Campaign groups are threatening legal action against the UK government over a drug pricing agreement with the United States, alleging that changes to NHS treatment approval processes violate the law.
The two organizations contend that modifications to how medicines gain approval for NHS use constitute an "unlawful power grab." These procedural changes could result in the health service paying higher prices for pharmaceuticals under the UK-US trade deal negotiated with the Trump administration.
The dispute centers on the approval mechanism itself. The campaigners argue the government has exceeded its statutory authority by altering the established framework through which drugs are evaluated before entering the NHS formulary. The change apparently bypasses or weakens existing oversight mechanisms, potentially allowing pharmaceutical companies greater leverage in price negotiations.
The UK-US pharmaceutical agreement drew fire from health advocates and NHS officials who warned it could strain public health budgets. The tension reflects a broader debate over trade-offs between securing favorable trade terms with the United States and protecting the NHS from cost pressures. American pharmaceutical companies typically charge higher prices than their European counterparts, partly because the US lacks price controls that other developed nations maintain.
The campaign groups' legal threat represents a significant escalation. If they proceed with court action, judges would need to determine whether the government acted within its legal authority when modifying the approval process. Such a ruling could force the administration to restore previous procedures or renegotiate deal terms.
The government has defended the agreement as necessary for securing a broader trade deal with the United States. Officials argue the arrangement protects the NHS's overall financial interests while maintaining access to innovative treatments. The dispute highlights tensions between the Labour government's priority of securing American trade relationships and its commitment to preserving the NHS as a publicly funded institution insulated from market pricing pressures.